For women with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy,

ZEJULA may keep you moving forward.*

Not actual ZEJULA patients.

*In a first-line maintenance clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. Results may vary. The trial is ongoing to see if patients live longer overall with treatment.

Why ZEJULA?

Learn about the features of ZEJULA

01

Why ZEJULA - Learn more about an oral, once-daily treatment option.

Discover more

02

Taking ZEJULA – Customized dosing and monitoring requirements.

SEE DETAILS

03

See clinical trial results.

Read the data